Rapport Therapeutics, Inc. Common Stock (RAPP) — Financial Flexibility Index

Latest as of June 2026: -1.51x

Rapport Therapeutics, Inc. Common Stock (RAPP) has a Financial Flexibility Index of -1.51x as of June 2026. Free cash flow of $-54.35 Million (operating CF $-54.52 Million minus capex $164.00K) represents -2% of total liabilities ($36.06 Million). Check tangible equity quality of Rapport Therapeutics, Inc. Common Stock to evaluate the tangible quality of the company's equity base.

Financial Flexibility Index

-1.51x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-54.35 Million
Operating CF − Capex

Total Liabilities

$36.06 Million
USD

Capital Expenditures

$164.00K
USD

Rapport Therapeutics, Inc. Common Stock Financial Flexibility Index (2022–2025)

Historical Financial Flexibility Index trend for Rapport Therapeutics, Inc. Common Stock across 4 annual periods. For the full cash flow conversion analysis, see RAPP cash flow conversion.

Annual Financial Flexibility Index for Rapport Therapeutics, Inc. Common Stock (2022–2025)

Year-by-year free cash flow to debt coverage for Rapport Therapeutics, Inc. Common Stock. Explore RAPP debt coverage from operations to assess how comfortably operating cash covers total debt obligations.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2025 -3.13x $-86.86 Million $-87.47 Million $27.78 Million ▲ +52.4%
2024 -6.57x $-62.42 Million $-64.83 Million $9.51 Million ▼ -4554.3%
2023 -0.14x $-25.55 Million $-27.18 Million $181.06 Million ▲ +42.3%
2022 -0.24x $-2.96 Million $-3.24 Million $12.10 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities